Jan Egbert de Vries

Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA.

Schering-Plough Research Institute provides pharmaceutical research. The company is headquartered in Kenilworth, NJ.

Cassiopea SpA is a clinical-stage specialty pharmaceutical company. It engages in developing and commercializing medical dermatology products focusing on the topical treatment of acne, androgenic alopecia, and genital warts. The firm's products include Winlevi, Breezula, Clascoterone Solution, CB-06-02, and CB-06-01. The company was founded on July 30, 2013 and is headquartered in Milan, Italy.

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek is a scientific research institute and a specialist clinic. The firm’s areas of research are including fundamental, clinical and translational cancer research. The company was founded in 1916 and is headquartered in Amsterdam, Netherlands.

AIMM Therapeutics BV develops therapeutic antibodies for the treatment of cancer and infectious diseases. Its antibody discovery platform couples proprietary knowledge of B cell immortalization with the isolation of antibodies from humans or animals. The company was founded by Donald Kalff and Hergen Spits in 2004 and is headquartered in Amsterdam, the Netherlands.

Tr1x, Inc. is an American biotechnology company. The company was founded by Jan Egbert de Vries. Jan Egbert de Vries has been the CEO since incorporation.